Novartis Double Setback Hits Biopharma Sector

Novartis and Ionis' closely watched Lp study failed last Friday, casting a lingering impact on biotech stocks and leading to notable declines on Tuesday. This dual setback triggered a ripple effect across the biopharmaceutical industry, with numerous stocks trending lower. The aftermath of Novartis' failed study continues to unfold, underscoring the significance of this event for investors.